HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo(c)chromen-1-ol

HCID 2978
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
16849-50-6
Standard SMILES
CCCCCc1cc(O)c2c(c1)OC(C)(C)C1CCC(C)=CC21
InChIKey
CYQFCXCEBYINGO-UHFFFAOYSA-N
Molecular formula
C21H30O2
Average molar mass
314.5 g/mol
Monoisotopic mass
314.2245802

Overview

6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol is a 1-benzopyran.

Names & identifiers

Preferred name
6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo(c)chromen-1-ol
IUPAC
6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol
English name
6a,7,8,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol
Molecular formula
C21H30O2
Molecular weight
314.46

Names & synonyms

DTXSID208596936,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo(c)chromen-1-olRefChem:1073561DTXCID102091086,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol16849-50-66a,7,8,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-olDelta 9-THCTHC, delta 9.DELTA.1-Tetrahydrocannabinol(-)-.DELTA.9-THC
Show more names
(L)-.delta.1-TetrahydrocannabinolCannabinol, .DELTA.1-tetrahydro-(-)-.DELTA.1-Tetrahydrocannabinol(-)-.DELTA.9-Tetrahydrocannabinol.DELTA.9-trans-TetrahydrocannabinolL-.delta.1-trans-TetrahydrocannabinolL-trans-.delta.9-Tetrahydrocannabinol(+)-?9-THC

Database identifiers

CAS
16849-50-6
PubChem CID
2978
DTXSID

Properties

Computed structural propertiesFilling in

XLogP
7
Topological polar surface area
29.5 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
2
Rotatable bonds
4
Heavy atoms
23
Formal charge
0
Complexity
439

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Toxicology

Treatment · 1 item

A potentially serious oral ingestion, if recent, should be managed with gut decontamination. In unconscious patients with a secure airway, instill activated charcoal (30 to 100 g in adults, 1 to 2 g/kg in infants) via a nasogastric tube. A saline cathartic or sorbitol may be added to the first dose of activated charcoal. Patients experiencing depressive, hallucinatory or psychotic reactions should be placed in a quiet area and offered reassurance. Benzodiazepines (5 to 10 mg diazepam po) may be used for treatment of extreme agitation. Hypotension usually responds to Trendelenburg position and IV fluids. Pressors are rarely required. (L1712)

Health Effects · 1 item

The heightened suggestibility and intensified emotions that hallucinogens create can worsen any pre-existing emotional problems. Physical effects of hallucinogen use include dilated pupils, sweating, insomnia, loss of appetite, tremors; and increased body temperature, heart rate and blood pressure.

Exposure RoutesOral
Toxicity Summary · 1 item

The mechanism of action of marinol is not completely understood. It is thought that cannabinoid receptors in neural tissues may mediate the effects of dronabinol and other cannabinoids. Animal studies with other cannabinoids suggest that marinol's antiemetic effects may be due to inhibition of the vomiting control mechanism in the medulla oblongata.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).

Chemistry & industry

Pharmacology

Metabolism/MetabolitesHepatic Route of Elimination: Dronabinol and its biotransformation products are excreted in both feces and urine. Half Life: Alpha phase: approximately 4 hours; Beta phase: 25-36 hours

Uses & manufacturing

UsesFor the treatment of anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments

Additional notes

DefinitionChEBI: 6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol is a 1-benzopyran.

Related reactions

6 records
New reaction record
HRID 166472 reaction equation
HRID 166472As reactant
HRID 267335 reaction equation
HRID 267335As reactant
HRID 267340 reaction equation
HRID 267340As reactant
HRID 2398880 reaction equation
HRID 2398880As reactant
HRID 2398882 reaction equation
HRID 2398882As reactant
HRID 2398886 reaction equation
HRID 2398886As reactant

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
DTXSID20859693
ChEBI
CHEBI:143723
Nikkaji
J280.524C